Join to View Full Profile
200 Corporate PointeSte 50Culver City, CA 90230
Phone+1 424-266-7474
Fax+1 310-596-8268
Dr. Bhatti is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Infectious Disease, 1996 - 1998
University of California (San Diego) Medical CenterResidency, Internal Medicine, 1994 - 1996
Stony Brook Medicine/University HospitalInternship, Internal Medicine, 1993 - 1994
UCLA School of MedicinePh.D, Immunology nd Microbiology, 1986 - 1992- UCLA School of MedicinePh.D., Microbiology and Immunology, 1986 - 1992
Certifications & Licensure
CA State Medical License 1995 - 2027
National Board of Physicians and Surgeons Infectious Disease- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Centricity EMR, GE Healthcare, 2014
- Ph.D UCLA School of Medicine, 1993
- Commendation for Dedicated Clinical Service to the County of Los Angeles 2006
Clinical Trials
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Publications & Presentations
PubMed
- 16 citationsTURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirDavid L. Wyles, Michael S. Saag, Rolando M Viani, Jacob Lalezari, Oluwatoyin Adeyemi
The Journal of Infectious Diseases. 2017-02-15 - 16 citationsThe ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/...David A. Wohl, Laveeza Bhatti, Catherine B. Small, Howard Edelstein, Henry H. Zhao
HIV Medicine. 2016-02-01 - 260 citationsOmbitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized TrialMark S. Sulkowski, Joseph J. Eron, David L. Wyles, Roger Trinh, J. Lalezari
JAMA. 2015-03-24
Journal Articles
- Turquoise-! Part 1b: Ombitasvir/Paritapavir/Ritonavir and Dasabuvir with Ribavarin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on DarunavirWyles D., Saag M., Viani R.M., Lalezari J., Adeyemi O., Bhatti L., Khatri A., King J.R., Hu Y.B., Trinh R., Shulman N.S., and Ruane P, JID, 1/1/2017
- Ombitasvir Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 - A Randomized TrialSulkowski M.S., Eron J.J., Wyles D., Trinh R., Lalezari J., Wang C., Slim J., Bhatti L., Gathe J., Ruane P.J., Elion R., Breedek F., Breenan R., Gary B., Khatri A., Gi..., JAMA, 1/1/2015
- Once Daily Nevirapine XR: A Brief Overview of the Safety and Efficacy of a New FormulationBhatti, L, and J. Gladstein, Journal of the International Association of Physicians in Aids Care, 1/1/2012
Abstracts/Posters
- Pilot Study Evaluating the Safety and Efficacy of Dose Sparing Intradermal Administration of Influenza Vaccine in HIV-Positive Patients.Khanlou,H., S. Sanchez, M. Babaie, C. Chien, J.C. Ricaurte, T. Stein, L. Bhatti, P. Denouden, A. Voskanian and C. Farthing, CROI, 1/1/2006
Lectures
- Efficacy and Safety of Switching from Boosted-protease Inhibitor Plus Emtricitabine/Tenofovir Disoproxil Fumarate Regimens to the Single-tablet Regimen of Darunavir/Co...Paris, France - 1/23/2017
- TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/r+Dasabuvir+RBV for HCV/HIV Coinfection.Boston, MA, 2016; Mendoza, Argentina, 2016 - 1/22/2016
- Improvement in Liver Fibrosis, Necroinflammatory Scores and Liver Function Tests in Achieving SVR with DAA Treatment in HIV/HEP-C Co-infected Patients in a Ryan White ...Moran, WY - 1/15/2016
Committees
- Advisory Committee Member, Aids Drug Assistance Program (ADAP) California
Professional Memberships
- Member
- Member
Other Languages
- Urdu, Hindi, Punjabi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
